Cedars Sinai Research Updates in Lymphoma 2025

Date & Location Saturday, October 18, 2025, 7:30 AM – Sunday, October 19, 2025, 3:00 PM PT, Cedars-Sinai Pavilion Education Center, Los Angeles, CA

Target Audience
Specialties – Hematology, Imaging, Internal Medicine, Oncology, Pathology & Laboratory Medicine, Radiation Oncology, Radiology, Surgery
Professions – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)

Overview
This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, “How I Treat” sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.
Objectives

Recognize the utility of molecular testing in the classification and treatment of lymphoma
Identify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma
Describe new treatments under development including bi specific antibodies and CART therapies
Collaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making

 
+ Topics:

Saturday, October 18, 2025

Session 1: Hot Topics in Clinical Lymphoma – Part I
Session Chair: TBD

Frontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates
8:10AM – 8:35AM
Joe Schroers-Martin, MD

Novel Approaches in First-Line DLBCL: Beyond R-CHOP POLARIX, Zilovertamab Vedotin + R-CHP Updates
8:35AM – 9:00AM
Matthew G. Mei, MD

Dual Targeting CART for Lymphoma
9:00AM – 9:25AM
Akil Merchant, MD

Break and Exhibits
9:25AM – 10:10AM

Session 2: Hot Topics in Clinical Lymphoma – Part II
Session Chair: Justin Darrah

T-Cell Lymphoma
10:10AM – 10:35AM
Wen-Kai Weng, MD, PhD

Role of Radiation Therapy in Lymphoma
10:35AM – 11:00AM
Parag Sanghvi, MD

Lightning Round

Lightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)
11:00AM – 11:30AM

Lunch and Networking

Lunch and Exhibits
11:30AM – 12:15PM

Session 3: Keynote & Basic Science Insights
Session Chair: Akil Merchant, MD

KEYNOTE ADDRESS: Spatial Profiling in Lymphoma Transformers: More than Meets the Eye
12:15PM – 1:00PM
Mina Xu, MD

Microenvironment in Non-Hodgkin Lymphoma
1:00PM – 1:20PM
Anthony R Colombo, PhD

Hidden Opponents: The DLBCL Microenvironment
1:20PM – 1:40PM
David Russler-Germain, MD, PhD

Metabolic Profiling and Modulation of the Lymphoma Microenvironment
1:40PM – 2:00PM
Akil Merchant, MD

Break and Exhibits
2:00PM – 2:20PM

Session 4: Next Generation Diagnostics and Biomarkers
Session Chair: Joseph C. Lownik, MD

Lymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling
2:20PM – 2:50PM
Lisa M Rimsza, MD

Developing an Automated Multiplex IF for Diagnostic/Biomarker Use in Lymphoma
2:50PM – 3:10PM
Joseph C. Lownik, MD

Role of ct DNA in Lymphoma
3:10PM – 3:30PM
Brian Sworder, MD, PhD

Assessments and Therapies for Older Patients with Aggressive Lymphomas
3:30PM – 3:50PM
Elizabeth Brem, MD

Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in DLBCL
3:50PM – 4:10PM
Sean R Corcoran , MD, PhD

Adjourn
4:10PM – 4:15PM

Networking Reception

Networking Reception
4:15PM – 5:30PM

Sunday, October 19, 2025

Session 1: CAR-T Cell Therapy: Managing Complex Toxicities
Session Chair: Hitomi Hosoya, MD, PhD

Mechanisms of Neurotoxicity with IEC and Bispecific Therapies
8:00AM – 8:20AM
Juliane Gust, MD, PhD

IEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management
8:20AM – 8:40AM
Hrishikesh Srinagesh, MD

Prophylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches
8:40AM – 9:00AM
Caspian Oliai, MD

Secondary and T-cell Malignancies after CAR T-cell Therapy
9:00AM – 9:20AM
Hitomi Hosoya, MD, PhD

Break and Exhibits
9:20AM – 9:35AM

Session 2: Clinical Debate–What is the Optimal Bridging Strategy for CAR-T Therapy
Session Chair: Justin Darrah, MD

Intro: Why bridging?
9:35AM – 9:40AM
Justin Darrah, MD

Role of Bispecifics as Bridging
9:40AM – 9:50AM
Justin Darrah, MD

Radiation as Bridging
9:50AM – 10:00AM
Parag Sanghvi, MD

Optimal Chemotherapy for Bridging
10:00AM – 10:10AM
David R. Oveisi, MD

Debate and Discussion
10:10AM – 10:35AM

BREAK/EXHIBITS
10:35AM – 11:05AM

Session 3: Next Generation Cellular Therapies for Lymphoma and Beyond (Non Accredited)
Session Chair: Yvonne Chen, PhD

Novel CART for Solid Tumors
11:05AM – 11:25AM
Yvonne Chen, PhD

Innovations in TIL Therapy
11:25AM – 11:50AM
Giri Ramsingh , MD

Macrophage Based Therapies
11:50AM – 12:10PM
Ann Liu, Other

Engineered Protein Circuits for Cancer Therapy
12:10PM – 12:30PM
Michael B. Elowitz, PhD

Closing and Lunch
12:30PM – 12:35PM